Opium (Opioid) Addiction – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Opium (Opioid) Addiction – Pipeline Review, H1 2018’, provides an overview of the Opium (Opioid) Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction

– The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects

– The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

Aoxing Pharmaceutical Company Inc

BioCorRx Inc

BioDelivery Sciences International Inc

Camurus AB

Fab'entech SA

Indivior Plc

Insys Therapeutics Inc

iX Biopharma Ltd

Nemus Bioscience Inc

Novartis AG

Omeros Corp

Opiant Pharmaceuticals Inc

Orexigen Therapeutics Inc

Orexo AB

Pfizer Inc

Relmada Therapeutics Inc

Syntropharma Ltd

Titan Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Opium (Opioid) Addiction Overview

Opium (Opioid) Addiction Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Opium (Opioid) Addiction Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Opium (Opioid) Addiction Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Aoxing Pharmaceutical Company Inc

BioCorRx Inc

BioDelivery Sciences International Inc

Camurus AB

Fab'entech SA

Indivior Plc

Insys Therapeutics Inc

iX Biopharma Ltd

Nemus Bioscience Inc

Novartis AG

Omeros Corp

Opiant Pharmaceuticals Inc

Orexigen Therapeutics Inc

Orexo AB

Pfizer Inc

Relmada Therapeutics Inc

Syntropharma Ltd

Titan Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc

Opium (Opioid) Addiction Drug Profiles

(buprenorphine + naloxone ) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(buprenorphine + naloxone) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(buprenorphine hydrochloride + naloxone hydrochloride) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

18-MC Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71441 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-88178 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANS-6637 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody for Poisoning, Drug Overdose and Opioid Addiction Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQU-010 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPRX-060312 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride depot Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine MR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Canquit-O Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-004 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mavoglurant Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-1104 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-2111 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-814 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-405 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPNT-005 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OREX-1019 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-4363467 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-5006739 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMZ-2123 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize D3 Receptor for Opioid Addiction Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Calcium Activated Potassium Channel, KOR1, and MOR1 for Chronic pain and Opioid Dependence Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Opium Addiction Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Opium (Opioid) Addiction Dormant Projects

Opium (Opioid) Addiction Discontinued Products

Opium (Opioid) Addiction Product Development Milestones

Featured News & Press Releases

Feb 13, 2018: Heroin vaccine blocks lethal overdose

Feb 12, 2018: BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102

Feb 08, 2018: Indivior Files Complaints Asserting New SUBOXONE Film Patent Against ANDA-filers

Jan 22, 2018: Titan In Discussions With Braeburn Regarding U.S. Probuphine Commercialization

Jan 21, 2018: Braeburn Receives Complete Response Letter for CAM2038 Injectable Buprenorphine Depot

Jan 05, 2018: BioCorRx Retains Regulatory Drug Expert Priya Jambhekar and CMC Expert Bruce Firestone

Jan 02, 2018: BioCorRx CEO, Brady Granier, Appears on Fox & Friends to Discuss the Opioid Epidemic

Dec 19, 2017: BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102

Dec 18, 2017: Opiant Pharma Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine

Dec 18, 2017: New Vaccine Technology Shows Promise as a Tool to Combat the Opioid Crisis

Nov 27, 2017: European Medicines Agency Accepts Titan Pharmaceuticals Marketing Authorization Application For Probuphine

Nov 20, 2017: Liberate Pain Management Introduces Suboxone Therapy and Other New Services

Nov 14, 2017: Opioid treatment drugs have similar outcomes once patients initiate treatment

Nov 07, 2017: Camurus to present at Jefferies 2017 London Healthcare Conference

Nov 01, 2017: Braeburn Announces FDA Advisory Committee Recommends Approval of CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Opium (Opioid) Addiction Pipeline by Addex Therapeutics Ltd, H1 2018

Opium (Opioid) Addiction Pipeline by Aoxing Pharmaceutical Company Inc, H1 2018

Opium (Opioid) Addiction Pipeline by BioCorRx Inc, H1 2018

Opium (Opioid) Addiction Pipeline by BioDelivery Sciences International Inc, H1 2018

Opium (Opioid) Addiction Pipeline by Camurus AB, H1 2018

Opium (Opioid) Addiction Pipeline by Fab'entech SA, H1 2018

Opium (Opioid) Addiction Pipeline by Indivior Plc, H1 2018

Opium (Opioid) Addiction Pipeline by Insys Therapeutics Inc, H1 2018

Opium (Opioid) Addiction Pipeline by iX Biopharma Ltd, H1 2018

Opium (Opioid) Addiction Pipeline by Nemus Bioscience Inc, H1 2018

Opium (Opioid) Addiction Pipeline by Novartis AG, H1 2018

Opium (Opioid) Addiction Pipeline by Omeros Corp, H1 2018

Opium (Opioid) Addiction Pipeline by Opiant Pharmaceuticals Inc, H1 2018

Opium (Opioid) Addiction Pipeline by Orexigen Therapeutics Inc, H1 2018

Opium (Opioid) Addiction Pipeline by Orexo AB, H1 2018

Opium (Opioid) Addiction Pipeline by Pfizer Inc, H1 2018

Opium (Opioid) Addiction Pipeline by Relmada Therapeutics Inc, H1 2018

Opium (Opioid) Addiction Pipeline by Syntropharma Ltd, H1 2018

Opium (Opioid) Addiction Pipeline by Titan Pharmaceuticals Inc, H1 2018

Opium (Opioid) Addiction Pipeline by Zynerba Pharmaceuticals Inc, H1 2018

Opium (Opioid) Addiction Dormant Projects, H1 2018

Opium (Opioid) Addiction Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Opium (Opioid) Addiction, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports